Industry-Expert Theaters
Expo Hall, #704 and #729

ACC.17 MediaConnect with the experts in the Industry-Expert Theater as presenters share the latest in cardiovascular practices, services and technologies while you enjoy refreshments or lunch — presentations are conveniently scheduled during the daily breaks.

  Saturday, March 10
  Saturday, March 10

The Underlying Thrombotic Risk in Patients With Atherosclerotic Vascular Disease
Theater 1, Expo Hall, #704
Kelley R. Branch, MD, MSc, FACC, FSCCT; Associate Professor in Cardiology, University of Washington Medical Center
Sponsored by Janssen Pharmaceuticals, Inc.

Coronary artery disease (CAD) and peripheral artery disease (PAD) are clinical manifestations of vascular disease, sharing common pathophysiologic characteristics of atherosclerosis and atherothrombosis. Both are associated with a persistent underlying thrombotic risk of recurrent cardiovascular events (MACE), which can confer significant morbidity and mortality. This presentation will discuss the prevalence, epidemiology, risk factors, and residual risk of CV events that exist in spite of current guidelines based treatment recommendations in managing these patient populations.

This session is open to ACC.18 attendees with full access badges only.

Criticality of LDL-C Lowering
Theater 2, Expo Hall, #729
Dr. James A. Underberg
Sponsored by Amgen

Optimizing Treatment to Improve Outcomes: Implementing the New Guideline for Managing Heart Failure With Reduced Ejection Fraction
Theater 1, Expo Hall, #704
Roberta Bogaev, MD; Medical Director, Advanced Heart Failure and Mechanical Circulatory Support Center, Bon Secours Advanced Heart Failure Center

Javed Butler, MD, MPH, MBA; Professor and Chair, Department of Medicine, University of Mississippi

Beth Davidson, DNP, ACNP, CHFN, CCRN; Director, HF Disease Management Program, TriStar Centennial Medical Center


Sponsored by Novartis Pharmaceuticals Corporation

Despite evidence-based pharmacologic therapy, morbidity and mortality rates associated with heart failure with reduced ejection fraction (HFrEF) remain high. Please join us as medical expert(s) engage(s) in discussions on the mechanism of action of a novel HFrEF therapy, its landmark clinical trial data, and an interactive HF patient case study.

Repatha® (evolocumab): Putting it into Practice (commercial presentations)
Theater 2, Expo Hall, #729
Benjamin J. Ansell, MD, FACP, FACC, FNLA
Sponsored by Amgen

The program provides an overview of Repatha®, including dosing and administration. A discussion of appropriate patients will be supplemented by relevant hypothetical examples.

The MR Decision Pathway: Delivering a Solution For High Risk Patients With Transcatheter Edge-To-Edge Mitral Valve Repair
Theater 1, Expo Hall, #704
Michael Mack, MD, FACC; Medical Director, Cardiovascular Surgery, Baylor Health Care Chairman, Heart Hospital Baylor Plano Research Center

Paul Grayburn, MD, FACC; Medical Director, Non-Invasive Cardiology, Baylor Hamilton Heart and Vascular Hospital, Medical Director, Cardiology Research and Education Baylor, University Medical Center

Saibal Kar, MD; Director, Interventional Cardiac Research, Associate Professor Medicine, Cedars-Sinai Medical Center

Raj Khandwalla, MD; Director, Cardiovascular Education, Cedars-Sinai Medical Care

Sponsored by Abbott

Mitral regurgitation, the most commonly reported valvular heart disease, is observed in approximately 10% of patients over the age of 75, yet only 1.5% of patients are treated. This symposium seeks to address the treatment gap using the recently published MR Decision Pathway as a framework for discussion. Using a case-based approach, the panelists will review patient assessment, including clinical and echocardiographic criteria, as well as the triggers for referral to a Heart Valve Team. Lastly, the audience will be guided through a transcatheter mitral valve repair procedure with the MitraClip, during which patient selection and implant techniques will be reviewed.

This session is open to ACC.18 attendees with full access badges only.

Jardiance® (empagliflozin) tablets: Evolving Clinical Development
Theater 2, Expo Hall, #729
Seth J. Baum, MD, FACC, FAHA, FACPM, FNLA, FASPC; President, The American Society for Preventive Cardiology; Founder & CMO, Excel Medical Clinical Trials

Pam R. Taub, MD, FACC; Associate Professor of Medicine, UC San Diego Health System

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA

This program will discuss recent data from the ongoing JARDIANCE clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for JARDIANCE.

Attendees will also have the opportunity to ask the faculty questions about the data presented.

This session is open to ACC.18 attendees with full access badges only.

  Sunday, March 11
  Sunday, March 11

Understanding Heart Failure From Bench to Bedside: The Role of Natriuretic Peptides
Theater 1, Expo Hall, #704
John C. Burnett, Jr, MD; Marriott Family Professor of Cardiovascular Research, Professor of Medicine and Physiology, Director, Cardiorenal Research Laboratory, Distinguished Mayo Investigator, Mayo Clinic

James L. Januzzi, Jr, MD, FACC, FESC; Hutter Family Professor of Medicine, Harvard Medical School Cardiology Division, Massachusetts General Hospital, Cardiometabolic Trial Group, Baim Institute for Clinical Research

Sponsored by Novartis Pharmaceuticals Corporation

Natriuretic peptides (NPs) play a protective role in heart failure (HF) by counteracting the deleterious effects of the renin‐angiotensin‐aldosterone system (RAAS) and the sympathetic nervous system (SNS). NPs are highly expressed early in the course of the disease and are instrumental in maintaining sodium balance and systemic hemodynamics. Owing to their central role in HF pathophysiology, NPs are key diagnostic and prognostic biomarkers in HF. Elevated levels of B‐type NP (BNP) and N‐terminal proBNP are associated with increased morbidity and mortality in patients with chronic HF. This program will review the role of NPs in balancing the activities of the RAAS and SNS, discuss the impacts of impaired NP activity on HF progression, and highlight the role of NPs as biomarkers of clinical activity in HF.

Risk Considerations in Patients With CHD and PAD
Theater 2, Expo Hall, #729
Dr. Ron Waksman
Sponsored by Amgen

Clinical Data and Real-World Evidence to Support NVAF & DVT/PE Treatment Decision Making
Theater 1, Expo Hall, #704
Dharmesh Patel, MD, FACC Cardiologist Stern Cardiovascular Foundation
Sponsored by Janssen Pharmaceuticals, Inc.

This lecture will present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.

This session is open to ACC.18 attendees with full access badges only.

Repatha® (evolocumab): Putting it Into Practice (commercial presentations)
Theater 2, Expo Hall, #729
Eliot A. Brinton, MD, FAHA, FNLA
Sponsored by Amgen

The program provides an overview of Repatha®, including dosing and administration. A discussion of appropriate patients will be supplemented by relevant hypothetical examples.

Inflammation in Atherosclerosis: Clinical Implications
Theater 1, Expo Hall, #704
Peter Libby, MD; Cardiovascular Specialist Brigham and Women’s Hospital Mallinckrodt Professor of Medicine Harvard Medical School Boston
Sponsored by Novartis Pharmaceuticals Corporation

Of the 17.3 million deaths resulting from cardiovascular disease each year, approximately 7.3 million are attributable to myocardial infarction (MI). Following an MI, many people can benefit from aggressive statin therapy that is aimed at cholesterol risk reduction. Additionally, patients who do not achieve the target low‐density lipoprotein cholesterol (LDL‐C) level on the maximum‐tolerated dose of statins may benefit from targeted therapies that further reduce LDL‐C levels. Still, the risk of life‐threatening vascular events after an initial MI is substantial. Vascular inflammation is a significant source of secondary risk for cardiovascular events in patients with a history of MI, contributing to all phases of atherosclerosis. Given the importance of inflammation in the disease process, evaluating inflammatory risk may be a reasonable approach for secondary prevention. Furthermore, distinguishing residual cholesterol risk from residual inflammatory risk may have clinical implications. This disease state presentation will highlight the role of inflammation in the pathophysiology of atherosclerosis and discuss approaches to reducing the residual risk of recurrent major cardiovascular events following MI.

Selecting the Right Therapy Option For NVAF Stroke Risk Reduction: A Multi-Specialty Approach
Theater 2, Expo Hall, #729

Devi Nair, MD, St. Bernard’s Heart & Vascular, Jonesboro, Arkansas

Jacqueline Saw, MD, Vancouver General Hospital, Vancouver, Canada

Sarika Desai, DO, Banner University, Medical Center, Phoenix, AZ

Christopher Granger, MD, Duke University Medical Center, Durham, NC

David Rose, MD, Tampa General Hospital, Tampa, FL


Sponsored by Boston Scientific

Join us for this unique program that will explore drug and device-based therapies for reducing stroke risk in patients with non-valvular atrial fibrillation from a cardiology, neurology, and interventionalist perspective.

This session is open to ACC.18 attendees with full access badges only.

  Monday, March 12
  Monday, March 12

Cardiovascular Disease Burden in the US and Clinical Evaluation of VASCEPA® (icosapent ethyl)
Theater 1, Expo Hall, #704
Speakers to be announced
Sponsored by Amarin Pharma, Inc.

This session is open to ACC.18 attendees with full access badges only.

Advancements in the Management of Patients With Type 2 Diabetes: Results From a Large Cardiovascular Outcomes Trial
Theater 2, Expo Hall, #729
Cres P. Miranda, Jr, MD, FACC, FACP, FSCAI; Interventional and Preventive Cardiologist, Nevada Heart and Vascular Center
Sponsored by Novo Nordisk

Program will review data on advancements in Type 2 Diabetes management from a large cardiovascular outcomes trial.

This session is open to ACC.18 attendees with full access badges only.

Protecting Patients at Risk of Sudden Cardiac Death: Results of the Vest Early Prevention of Sudden Death (VEST) Trial
Theater 1, Expo Hall, #704
Jeffrey Olgin, MD; Chief, Division of Cardiology, Co-Director, Heart and Vascular Center, University of California San Francisco
Sponsored by ZOLL Medical

This program will present data and results from the VEST trial. Discussion will focus on the protection of patients from Sudden Cardiac Death using a Wearable Cardioverter Defibrillator.

Long-Term Results of Treatment Across a Broad Range of Patients With Type 2 Diabetes
Theater 2, Expo Hall, #729
Javed Butler, MD, MPH, MBA; Professor and Chair, Department of Medicine, University of Mississippi
Sponsored by Janssen Pharmaceuticals, Inc.

Schedule is current as of Feb. 9, 2018, and is subject to change. Please check back for updates.


* Industry-Expert Theater presentations are not part of ACC.18, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

Advertisement

ACC Logo
ACC.18 on Social Media:
      
2017 American College of Cardiology Foundation. Visit ACC.org
Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Contact Us